Hong, D. S., Bang, Y.-J., Barlesi, F., Durm, G., Falchook, G. S., Govindan, R., … Li, B. T. (2020). 381MO Durability of clinical benefit and biomarkers in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with AMG 510 (sotorasib). In Annals of Oncology (Vol. 31, pp. S1389–S1390). Elsevier BV. https://doi.org/10.1016/j.annonc.2020.10.375

Hong, D. S., Y. -. J. Bang, F. Barlesi, G. Durm, G. S. Falchook, R. Govindan, G. K. Dy, et al. “381MO Durability of clinical benefit and biomarkers in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with AMG 510 (sotorasib).” In Annals of Oncology, 31:S1389–90. Elsevier BV, 2020. https://doi.org/10.1016/j.annonc.2020.10.375.

Hong DS, Bang Y-J, Barlesi F, Durm G, Falchook GS, Govindan R, et al. 381MO Durability of clinical benefit and biomarkers in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with AMG 510 (sotorasib). In: Annals of Oncology. Elsevier BV; 2020. p. S1389–90.

Hong, D. S., et al. “381MO Durability of clinical benefit and biomarkers in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with AMG 510 (sotorasib).” Annals of Oncology, vol. 31, Elsevier BV, 2020, pp. S1389–90. Crossref, doi:10.1016/j.annonc.2020.10.375.

Hong DS, Bang Y-J, Barlesi F, Durm G, Falchook GS, Govindan R, Dy GK, Park K, Strickler JH, Burns TF, Kim J, Ang A, Lipford JR, Ngarmchamnanrith G, Anderson A, Li BT. 381MO Durability of clinical benefit and biomarkers in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with AMG 510 (sotorasib). Annals of Oncology. Elsevier BV; 2020. p. S1389–S1390.